Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children

Issraa Al-Obaidi, Anna K. Krome, Karl G. Wagner, Kenneth Pfarr, Annette C. Kuesel, Hannah K. Batchelor*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)
17 Downloads (Pure)

Abstract

It is recognised that paediatric indications and age-appropriate formulations are required to ensure that paediatric populations receive appropriate pharmacotherapeutic treatment. The lack of information on dosing, efficacy and safety data (labelling) is a well-recognised problem for all diseases affecting children. For neglected tropical diseases, the fact that they affect to a large extent poor and marginalised populations in low- and middle-income countries means that there is a low economic return on investment into paediatric development activities compared to other diseases [e.g. human immunodeficiency virus (HIV)]. This review provides an introduction to issues affecting the availability and development of paediatric population-relevant data and appropriate formulations of drugs for NTDs. We are summarising why age-appropriate formulations are important to ensure treatment efficacy, safety and effectiveness, outline initiatives to increase the number of paediatric indications/labelling and age-appropriate formulations, provide an overview of publicly available information on the formulations of oral drugs for NTDs relative to age appropriateness and give an introduction to options for age-appropriate formulations. The review completes with ‘case studies’ of recently developed paediatric formulations for NTDs, complemented by case studies for fixed-dose combinations for HIV infection in children since such formulations have not been developed for NTDs. Graphical Abstract: [Figure not available: see fulltext.].

Original languageEnglish
Article number462
Number of pages22
JournalParasites and Vectors
Volume15
Issue number1
DOIs
Publication statusPublished - 12 Dec 2022

Funding

This review is part of the MiniMox project for development of a paediatric moxidectin formulation ( https://minimox.squarespace.com/ ). That project is part of the EDCTP2 programme supported by the European Union (RIA2019PD-2880) and co-funded by Medicines Development for Global Health and the Fonds National de la Recherche Luxembourg (FNR n° INTER/EDCTP/19/14338294/MiniMox/Vaillant).

Keywords

  • neglected tropical diseases
  • NTD
  • oral formulation
  • paediatric age-appropriate formulations
  • paediatric indications
  • preventive chemotherapy
  • WHO roadmap

Fingerprint

Dive into the research topics of 'Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children'. Together they form a unique fingerprint.

Cite this